Cagrilintide dosage chart
This summary table compares available dose amounts and schedules by administration route.
| Route | Dose | Frequency & duration |
|---|---|---|
| Injectable | 0.3–4.5 mg | Once weekly · 26 weeks (monotherapy) |
Cagrilintide dosage by administration route
Cagrilintide injectable dosage
Single-agent subcutaneous schedules use 0.3–4.5 mg once weekly, with dose levels of 0.3, 0.6, 1.2, 2.4 or 4.5 mg over a 26-week course. Dose escalation spans up to the first 6 weeks. A lower-dose reported progression uses 0.16 mg once weekly for weeks 1–4, 0.3 mg for weeks 5–8, 0.6 mg for weeks 9–12, 1.2 mg for weeks 13–16 and 2.4 mg from week 17. This is a separate schedule from the 26-week single-agent course.[1][12]
Cagrilintide is a long-acting amylin analogue that acts on satiety signaling. Monotherapy and the semaglutide combination have distinct dose-escalation and safety requirements.[1][2][3]
Cycle length and breaks
Injectable: 26 weeks (monotherapy). A standard break interval between courses is not established.[1]
Cagrilintide dosage calculator
Convert your chosen Cagrilintide amount into volume and U-100 syringe units. Adjust the inputs to match your vial and preparation.
Cagrilintide safety and side effects
Side effects and long-term safety
Nausea and related gastrointestinal effects are important tolerability concerns. Rare events, long-term use, discontinuation effects and special-population safety remain uncertain. Hypoglycemia is also relevant in diabetes care.[1][2][6][7][9][8]
Route-specific dosing limits
Cagrilintide remains investigational, without an approved product label. Combination exposure with semaglutide or other satiety drugs needs separate assessment. Additional schedules attributed to Everything Peptide are reported patterns; citing research does not make these schedules clinically established or approved product instructions.[5][2][3][6][8][12]
Common Cagrilintide dosage questions
What is the weekly single-agent Cagrilintide dosage?
Does Cagrilintide have a standard cycle or break interval?
Injectable: 26 weeks (monotherapy). A standard break interval between courses is not established.[1]
Sources
Show citationsHide citations
- [1]Once-weekly cagrilintide for weight management in people with overweight and obesityThe Lancet. human clinical.
- [2]Cagrilintide plus semaglutide in people with overweight or obesity: a randomised phase 1b trialThe Lancet. human clinical.
- [3]Coadministered cagrilintide and semaglutide in adults with overweight or obesityNew England Journal of Medicine. human clinical.
- [4]Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-RegressionDiabetes, obesity & metabolism, 2026. review.
- [5]Search Drugs@FDA for cagrilintideopenFDA / U.S. Food and Drug Administration. database query.
- [6]REDEFINE 1 CagriSema obesity trial registry recordClinicalTrials.gov. clinical trial registry.
- [7]REDEFINE 2 CagriSema type 2 diabetes obesity trial registry recordClinicalTrials.gov. clinical trial registry.
- [8]Search Drugs@FDA for CagriSemaopenFDA / U.S. Food and Drug Administration. database query.
- [9]Cagrilintide and semaglutide co-administration in type 2 diabetesThe Lancet. human clinical.
- [10]FDA's concerns with unapproved GLP-1 drugs used for weight lossU.S. Food and Drug Administration. official guidance.
- [11]Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetesNew England Journal of Medicine. human clinical.
- [12]Cagrilintide — Everything Peptide reported protocol (educational reference, not clinical evidence)Everything Peptide. reference catalog.


